Ranawaka R, Dayasiri K, Sandamali E, Gamage M. Management strategies for common viral infections in pediatric renal transplant recipients. World J Transplant 2024; 14(1): 89978 [PMID: 38576764 DOI: 10.5500/wjt.v14.i1.89978]
Corresponding Author of This Article
Randula Ranawaka, MBBS, MD, Chief Physician, Professor, Senior Researcher, Department of Paediatrics, Faculty of Medicine, University of Colombo and Lady Ridgeway Hospital for Children, Kynsey Road, Colombo 0094, Sri Lanka. randula@pdt.cmb.ac.lk
Research Domain of This Article
Transplantation
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Transplant. Mar 18, 2024; 14(1): 89978 Published online Mar 18, 2024. doi: 10.5500/wjt.v14.i1.89978
Table 1 Pre-transplant screening and diagnostic work-up for kidney transplant recipients
CMV
CMV IgG serology in both donors and recipients
EBV
Screening by EBV serology in both donors and recipients
BKPyV
Not done at present
HSV
HSV antibodies in blood
VZV
Pretransplant screening for previous VZV infectio
Hepatitis B & C
HBV
HBsAg and antibody to hepatitis B core antigen (antiHBc)
HCV
HCV antibody test
Respiratory viruses
Nasopharyngeal wash or bronchoalveolar lavage fluid (BAL) specimens (in the case of Adeno virus - stools or plasma), by conventional viral culture, PCR, or direct immunofluorescence
Table 2 Post-transplant screening and diagnostic work-up for kidney transplant recipients
CMV
Quantitative CMV viral load
Diagnosis- presence of CMV DNA in whole blood or plasma
Tissue biopsy
Diagnosis- presence of CMV inclusion or immunostaining
CMV serology
Diagnosis- presence of CMV IgG post kidney transplantation in
CMV R- patients
EBV
Quantitative EBV viral load
Tissue biopsy
EBV serology
BKPyV
Urine cytology
Quantitative BK viral load in urine
Quantitative BK viral load in plasma
Allograft biopsy
HSV
Direct fluorescence antibody for HSV from vesicular lesions or PCR from CSF or visceral tissue samples
VZV
Direct fluorescence antibody for VZV from vesicular lesions or PCR from CSF or visceral tissue samples
Hepatitis B & C
HBV
HBsAg and antibody to hepatitis B core antigen (antiHBc)
HCV
HCV antibody test
Respiratory viruses
Nasopharyngeal wash or bronchoalveolar lavage fluid (BAL) specimens, (in the case of Adeno virus - stools or plasma), by conventional viral culture, PCR, or direct immunofluorescence
Table 3 Treatment of viral infections kidney transplant recipients
CMV
CMV load copy no < 500 - below quantifiable level - no action
CMV load copy no 500-3000 - active CMV infection - repeat CMV in 1 week, consider treatment if clinically indicated
CMV load copy no > 3000 - Active CMV infection - commence pre-emptive treatment
Intravenous ganciclovir or oral valganciclovir
EBV
Immunosuppressive drug reduction
Ganciclovir and valganciclovir have antiviral impact against EBV
BKPyV
Immunosuppressive drug reduction
No specific antiviral therapy
HSV
Acyclovir
Intravenous or oral
VZV
Intravenous acyclovir, while less severe infection can be treated with oral acyclovir
Hepatitis B & C
Immunosuppressive drug reduction
Hepatitis B – Lamivudine
Hepatitis C - IFN and ribavirin
Respiratory viruses
Reduce immunosuppressive drugs
Supportive care and, in some cases, the use of antivirals
Table 4 Prevention of viral infections kidney transplant recipients
CMV
Valganciclovir
Universal prophylaxis - Dose (mg) = (7 × BSA × eGFR) once a day
EBV viral load surveillance and preemptive therapy for EBV mismatched patients
BKPyV
BK viral load monitoring and early identification of BK viremia
HSV
Avoidance of visitors or health professionals who have HSV signs and symptoms
VZV
Avoidance of visitors or health professionals who have VZV signs and symptoms. Vaccination including family members
Hepatitis B & C
Hepatitis B vaccination and immunity verified with Hepatitis B surface antibody screening following completion of the vaccination series
Respiratory viruses
Avoidance of other individuals who have signs or symptoms of infection, hand hygiene, and use of droplet precautions for those suspected of having infection
Citation: Ranawaka R, Dayasiri K, Sandamali E, Gamage M. Management strategies for common viral infections in pediatric renal transplant recipients. World J Transplant 2024; 14(1): 89978